The U.S. Food and Drug Administration approved GSK’s Jideytro (zidesamtinib) for adult patients with ROS1-positive advanced non-small cell lung cancer. This treatment targets patients who have previously received a ROS1 inhibitor.
The approval follows GSK’s $10.6 billion acquisition of Nuvalent Bio, which closed last week. This regulatory success marks a rapid return on investment for the company. The acquisition also added another lung cancer candidate, neladalkib, to GSK’s pipeline.
GSK projects Jideytro has multi-blockbuster potential. Approximately 50,000 people receive a ROS1-positive lung cancer diagnosis globally each year. This approval marks GSK’s entry into this specific segment of the oncology market.